Full-dose blood thinners benefit moderately ill COVID-19 patients
REMAP-CAP an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.
Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19
Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 - a recently published report discusses a trial that employed #REMAP-CAP as one of its three collaborating platforms.
